viewProactive Group

Shares of Bellicum Pharmaceuticals set to gain after FDA lifts hold on study of cell therapy treatment

The company agreed with FDA to amend its study protocols

Lab worker
The stock climbed on the news

Shares of Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM) advanced after the company said the U.S. Federal Drug Administration (FDA) has lifted a hold on the clinical study of its BPX-501 T-cell therapy.

The firm focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. Its stock climbed 20% to US$8.16 in pre-market trading.

Amend study protocols

The decision by the FDA was made after the company agreed to amend study protocols, Bellicum said in a statement.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Ridgeline Minerals completes their Phase 3 drilling program at Selena...

Ridgeline Minerals (CVE: RDG) CEO Chad Peters joined Steve Darling to share details about the exploration company with 4 assets in the Carlin and Battle Mountain – Eureka Trends in Nevada.  Peters telling Proactive about their recent news including the completion of the Phase 3 drilling...

44 minutes ago

2 min read